Target intelligence / Profile preview

Dynamin-3 (DNM3)

Target
DNM3
Molecular classification
Enzyme, GTPase, Dynamin superfamily protein
01

Overview

Dynamin-3 (DNM3) is a member of the dynamin superfamily of large GTPases involved in membrane remodeling, fission, and vesicle formation[1][5][6]. DNM3 possesses a N-terminal GTPase domain, pleckstrin homology (PH) domain for membrane interaction, and a proline/arginine-rich domain (PRD) that serves as a hub for binding SH3 domain-containing proteins[1][2][6]. DNM3 is critical for clathrin-mediated endocytosis, functioning in the scission of vesicles from the plasma membrane and regulating receptor trafficking, especially in neurons where it mediates postsynaptic receptor recycling through interaction with adaptor proteins such as Homer[3]. DNM3 also plays an essential role in megakaryocyte development and platelet biogenesis, influencing progenitor amplification, cytoplasmic enlargement, and demarcation membrane system (DMS) formation[1]. Disruption or knockdown of DNM3 significantly impairs megakaryocyte maturation and can reduce platelet production[1]. While DNM3 is implicated in neurobiology, metabolism, and hematopoiesis, it is not currently the direct target of any approved therapeutic agents and remains primarily a subject of basic and translational research.

Other names
Dynamin-3DNM3KIAA0820Dynamin, testicularT-dynaminDyna IIIdynamin family member
02

Mechanism of action

Inhibition of dynamin GTPase activity (experimental compounds only), disruption of vesicle fission and endocytosis

03

Biological functions

Membrane fissionEndocytosisVesicle traffickingCytokinesisActin cytoskeleton remodelingReceptor recyclingCell motilityMegakaryocyte developmentPlatelet biogenesis
04

Disease associations

Neurodegenerative diseaseObesity/metabolic regulationPlatelet disordersPotential cancer relevance
05

Safety considerations

Potential hematologic complications (e.g., impaired platelet formation)Neurological effects due to broad role in synaptic function and membrane traffickingSpecificity concerns due to the conserved nature of dynamin family proteins
06

Interacting drugs

No approved drugs specifically targeting Dynamin-3 documented in current literature

1 more in the full profile.

07

Biomarkers

No validated biomarkers for patient selection or efficacy monitoring for Dynamin-3 as of current literature

Beyond the preview

Go deeper on Dynamin-3 (DNM3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dynamin-3 (DNM3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call